Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J F Wernicke

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
The Journal of Clinical Psychiatry|March 1, 1985
The side effect profile and safety of fluoxetineJ F Wernicke
Seminars in Urology|May 1, 1990
Approaches for the development of oral drug therapies for erectile dysfunctionM M Foreman, J F Wernicke
Journal of Neuroscience Research|January 1, 1986
Glial differentiation in dissociated cell cultures of neonatal rat brain: noncoordinate and density-dependent regulation of oligodendroglial enzymesJ F Wernicke, J J Volpe
The Journal of Clinical Psychiatry|February 4, 2003
Safety profile of atomoxetine in the treatment of children and adolescents with ADHDJ F Wernicke, Christopher J Kratochvil
The Laryngoscope|October 1, 1994
Safety and tolerability of the implantable recurrent laryngeal nerve stimulatorM Friedman, J F Wernicke, D D Caldarelli
International Clinical Psychopharmacology|January 1, 1989
Fluoxetine at 20 mg per day: the recommended and therapeutic dose in the treatment of depressionJ F Wernicke, J C Bosomworth, E Ashbrook
Journal of Neurochemistry|May 1, 1974
Beta-neurotoxin reduces neurotransmitter storage in brain synapsesJ F Wernicke, T Oberjat, B D Howard
Pacing and Clinical Electrophysiology : PACE|October 1, 1992
Treatment of refractory partial seizures: preliminary results of a controlled studyL K Holder, J F Wernicke, W B Tarver
Psychopharmacology Bulletin|January 1, 1990
Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depressionC M Beasley, J C Bosomworth, J F Wernicke
Journal of Neurochemistry|October 1, 1975
The mechanism of action of beta-bungarotoxinJ F Wernicke, A D Vanker, B D Howard
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Psychiatry|March 1, 1985
The side effect profile and safety of fluoxetineJ F Wernicke
Seminars in Urology|May 1, 1990
Approaches for the development of oral drug therapies for erectile dysfunctionM M Foreman, J F Wernicke
Journal of Neuroscience Research|January 1, 1986
Glial differentiation in dissociated cell cultures of neonatal rat brain: noncoordinate and density-dependent regulation of oligodendroglial enzymesJ F Wernicke, J J Volpe
The Journal of Clinical Psychiatry|February 4, 2003
Safety profile of atomoxetine in the treatment of children and adolescents with ADHDJ F Wernicke, Christopher J Kratochvil
The Laryngoscope|October 1, 1994
Safety and tolerability of the implantable recurrent laryngeal nerve stimulatorM Friedman, J F Wernicke, D D Caldarelli
International Clinical Psychopharmacology|January 1, 1989
Fluoxetine at 20 mg per day: the recommended and therapeutic dose in the treatment of depressionJ F Wernicke, J C Bosomworth, E Ashbrook
Journal of Neurochemistry|May 1, 1974
Beta-neurotoxin reduces neurotransmitter storage in brain synapsesJ F Wernicke, T Oberjat, B D Howard
Pacing and Clinical Electrophysiology : PACE|October 1, 1992
Treatment of refractory partial seizures: preliminary results of a controlled studyL K Holder, J F Wernicke, W B Tarver
Psychopharmacology Bulletin|January 1, 1990
Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depressionC M Beasley, J C Bosomworth, J F Wernicke
Journal of Neurochemistry|October 1, 1975
The mechanism of action of beta-bungarotoxinJ F Wernicke, A D Vanker, B D Howard
Pageof 4